2-Methoxyestradiol Affects Mitochondrial Biogenesis Pathway and Succinate Dehydrogenase Complex Flavoprotein Subunit A in Osteosarcoma Cancer Cells.

BACKGROUND/AIM Dysregulation of mitochondrial pathways is implicated in several diseases, including cancer. Notably, mitochondrial respiration and mitochondrial biogenesis are favored in some invasive cancer cells, such as osteosarcoma. Hence, the aim of the current work was to investigate the effects of 2-methoxyestradiol (2-ME), a potent anticancer agent, on the mitochondrial biogenesis of osteosarcoma cells. MATERIALS AND METHODS Highly metastatic osteosarcoma 143B cells were treated with 2-ME separately or in combination with L-lactate, or with the solvent (non-treated control cells). Protein levels of α-syntrophin and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1α) were determined by western blotting. Impact of 2-ME on mitochondrial mass, regulation of cytochrome c oxidase I (COXI) expression, and succinate dehydrogenase complex flavoprotein subunit A (SDHA) was determined by immunofluorescence analyses. Inhibition of sirtuin 3 (SIRT3) activity by 2-ME was investigated by fluorescence assay and also, using molecular docking and molecular dynamics simulations. RESULTS L-lactate induced mitochondrial biogenesis pathway via up-regulation of COXI. 2-ME inhibited mitochondrial biogenesis via regulation of PGC-1α, COXI, and SIRT3 in a concentration-dependent manner as a consequence of nuclear recruitment of neuronal nitric oxide synthase and nitric oxide generation. It was also proved that 2-ME inhibited SIRT3 activity by binding to both the canonical and allosteric inhibitor binding sites. Moreover, regardless of the mitochondrial biogenesis pathway, 2-ME affected the expression of SDHA. CONCLUSION Herein, mitochondrial biogenesis pathway regulation and SDHA were presented as novel targets of 2-ME, and moreover, 2-ME was demonstrated as a potent inhibitor of SIRT3. L-lactate was confirmed to exert pro-carcinogenic effects on osteosarcoma cells via the induction of the mitochondrial biogenesis pathway. Thus, L-lactate level may be considered as a prognostic biomarker for osteosarcoma.

[1]  Olli T. Pentikäinen,et al.  MMGBSA As a Tool To Understand the Binding Affinities of Filamin-Peptide Interactions , 2013, J. Chem. Inf. Model..

[2]  I. Blair,et al.  Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine* , 2015, The Journal of Biological Chemistry.

[3]  Adrià Cereto-Massagué,et al.  The good, the bad and the dubious: VHELIBS, a validation helper for ligands and binding sites , 2013, Journal of Cheminformatics.

[4]  Jan H. Jensen,et al.  Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. , 2011, Journal of chemical theory and computation.

[5]  M. Yaszemski,et al.  2‐methoxyestradiol‐induced cell death in osteosarcoma cells is preceded by cell cycle arrest , 2008, Journal of cellular biochemistry.

[6]  Nektarios Tavernarakis,et al.  Mitophagy and age‐related pathologies: Development of new therapeutics by targeting mitochondrial turnover , 2017, Pharmacology & therapeutics.

[7]  M. Abdellatif,et al.  Mitochondrial complex II is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival , 2015, Cell Death and Disease.

[8]  E. Clementi,et al.  Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide , 2003, Science.

[9]  M. Agnello,et al.  A method for measuring mitochondrial mass and activity , 2008, Cytotechnology.

[10]  K. Sotlar,et al.  Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas. , 2005, Anticancer research.

[11]  A. Verma,et al.  Physiologic Levels of 2-Methoxyestradiol Interfere with Nongenomic Signaling of 17β-Estradiol in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[12]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[13]  J. Neuzil,et al.  Mitochondrial complex II, a novel target for anti-cancer agents. , 2013, Biochimica et biophysica acta.

[14]  A. Tsirigos,et al.  Ketones and lactate “fuel” tumor growth and metastasis , 2010, Cell cycle.

[15]  E. Verdin,et al.  A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells. , 2016, Anticancer research.

[16]  D. Roy,et al.  Estrogen, mitochondria, and growth of cancer and non-cancer cells , 2005, Journal of carcinogenesis.

[17]  S. Bera,et al.  The transcriptional cascade associated with creatine kinase down-regulation and mitochondrial biogenesis in mice sarcoma , 2009, Cellular & Molecular Biology Letters.

[18]  Xiuping Liu,et al.  Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells. , 2013, Biochemical pharmacology.

[19]  Siva Lavu,et al.  Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3. , 2013, Journal of medicinal chemistry.

[20]  R. Santi,et al.  Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation. , 2017, Anticancer research.

[21]  Y. Song,et al.  Anticancer Strategy Targeting Mitochondrial Biogenesis in Ovarian Cancer , 2014 .

[22]  D. Winge,et al.  Succinate dehydrogenase - Assembly, regulation and role in human disease. , 2010, Mitochondrion.

[23]  S. Nussberger,et al.  2-Methoxyestradiol Reverses the Pro-Carcinogenic Effect of L-Lactate in Osteosarcoma 143B Cells. , 2017, Cancer genomics & proteomics.

[24]  M. Scholle,et al.  Discovery of SIRT3 Inhibitors Using SAMDI Mass Spectrometry , 2015, Journal of biomolecular screening.

[25]  M. Ciriolo,et al.  Nuclear Recruitment of Neuronal Nitric-oxide Synthase by α-Syntrophin Is Crucial for the Induction of Mitochondrial Biogenesis* , 2013, The Journal of Biological Chemistry.

[26]  C. Steegborn,et al.  Crystal structures of Sirt3 complexes with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism. , 2013, Chemistry & biology.

[27]  M. Harrison,et al.  A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC) , 2011, Investigational New Drugs.

[28]  Giosuè Lo Bosco,et al.  2‐methoxyestradiol impacts on amino acids‐mediated metabolic reprogramming in osteosarcoma cells by its interaction with NMDA receptor , 2017, Journal of cellular physiology.

[29]  R. Kalluri,et al.  Corrigendum: PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis , 2014, Nature Cell Biology.

[30]  J. Liu,et al.  Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer , 2014, Cell Death and Disease.

[31]  R. Friesner,et al.  The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling , 2011, Proteins.

[32]  Y. Takakura,et al.  Growth inhibition and induction of apoptosis by 2-methoxyestradiol in rat osteosarcoma and malignant fibrous histiocytoma cell lines. , 2008, In vivo.

[33]  J. Neuzil,et al.  Mitochondrial Complex II: At the Crossroads. , 2017, Trends in biochemical sciences.

[34]  Nektarios Tavernarakis,et al.  Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis , 2014, Experimental Gerontology.

[35]  J. Vicencio,et al.  PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. , 2012, Mitochondrion.

[36]  R. Houlgatte,et al.  PGC-1-Related Coactivator Modulates Mitochondrial-Nuclear Crosstalk through Endogenous Nitric Oxide in a Cellular Model of Oncocytic Thyroid Tumours , 2009, PloS one.

[37]  Priyanka Parihar,et al.  Mitochondrial sirtuins: Emerging roles in metabolic regulations, energy homeostasis and diseases , 2015, Experimental Gerontology.

[38]  F. Sotgia,et al.  Mitochondrial biogenesis drives tumor cell proliferation. , 2011, The American journal of pathology.

[39]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[40]  P. Puigserver,et al.  PGC-1 Coactivators: Shepherding the Mitochondrial Biogenesis of Tumors. , 2016, Trends in cancer.

[41]  M. Żmijewski,et al.  Neuronal Nitric Oxide Synthase Induction in the Antitumorigenic and Neurotoxic Effects of 2-Methoxyestradiol , 2014, Molecules.

[42]  S. Avnet,et al.  Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells , 2014, Oncotarget.

[43]  A. Hoeflich,et al.  Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. , 2013, Mitochondrion.

[44]  C. Moraes,et al.  NO control of mitochondrial function in normal and transformed cells. , 2017, Biochimica et biophysica acta. Bioenergetics.

[45]  M. Wozniak,et al.  Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol. , 2016, Anticancer research.

[46]  J. Meyerhardt,et al.  A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[47]  D. Matei,et al.  Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. , 2009, Gynecologic oncology.

[48]  J. Sławek,et al.  New Insight into 2-Methoxyestradiol- a Possible Physiological Link between Neurodegeneration and Cancer Cell Death. , 2016, Current medicinal chemistry.

[49]  D. Bofinger,et al.  A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion. , 2015, Journal of visualized experiments : JoVE.

[50]  Z. Xiang,et al.  On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.

[51]  Jin Han,et al.  Current and upcoming mitochondrial targets for cancer therapy. , 2017, Seminars in cancer biology.

[52]  P. Brookes,et al.  Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5 , 2017, ChemMedChem.

[53]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[54]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[55]  A. Grimm,et al.  Brain aging and neurodegeneration: from a mitochondrial point of view , 2017, Journal of neurochemistry.

[56]  J. Villena New insights into PGC‐1 coactivators: redefining their role in the regulation of mitochondrial function and beyond , 2015, The FEBS journal.

[57]  E. Petricoin,et al.  The Warburg Effect and Mass Spectrometry-based Proteomic Analysis. , 2017, Cancer genomics & proteomics.

[58]  S. Moncada,et al.  Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol. , 2004, Biochemical and biophysical research communications.

[59]  F. Cappello,et al.  DNA strand breaks induced by nuclear hijacking of neuronal NOS as an anti-cancer effect of 2-methoxyestradiol , 2015, Oncotarget.

[60]  Yoshinori Hirano,et al.  An Efficient Computational Method for Calculating Ligand Binding Affinities , 2012, PloS one.

[61]  I. Rzeszutek,et al.  Neuronal Nitric Oxide Synthase-Mediated Genotoxicity of 2-Methoxyestradiol in Hippocampal HT22 Cell Line , 2015, Molecular Neurobiology.

[62]  Juan Wang,et al.  Human SIRT3 tripeptidic inhibitors containing N(ε)-thioacetyl-lysine. , 2015, Bioorganic & medicinal chemistry letters.

[63]  M. Monsalve,et al.  Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  M. Karbowski,et al.  Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. , 2001, Journal of cell science.

[65]  Thomas Simonson,et al.  Protein side chain conformation predictions with an MMGBSA energy function , 2016, Proteins.

[66]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.